0-32259
|
94-3267295
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
881
Martin Avenue, Santa Clara, California
|
95050
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Exhibit
No.
|
Description
|
99.1
|
Press
Release of Align Technology, Inc. dated October 28,
2008
|
ALIGN
TECHNOLOGY, INC.
|
||
By:
|
/s/Kenneth
B. Arola
|
|
Kenneth
B. Arola
|
||
Vice
President, Finance and Chief Financial
Officer
|
Exhibit
No.
|
Description
|
99.1
|
Press
Release of Align Technology, Inc. dated October 28,
2008
|
Press
Contact
|
||
Shirley
Stacy
|
Shannon
Mangum Henderson
|
|
Align
Technology, Inc.
|
Ethos
Communication, Inc.
|
|
(678)
540-9222
|
||
sstacy@aligntech.com
|
align@ethoscommunication.com
|
Key
GAAP Operating Results
|
Q3
08
|
Q2
08
|
Q3
07
|
|||||||
Gross
Margin
|
75.0
|
%
|
74.7
|
%
|
74.6
|
%
|
||||
Operating
Expense
|
$
|
50.7M
|
$
|
55.8M
|
$
|
44.9M
|
||||
Operating
Margin
|
7.6
|
%
|
4.8
|
%
|
11.7
|
%
|
||||
Net
Profit
|
$
|
5.2M
|
$
|
4.0M
|
$
|
9.5M
|
||||
Earnings
Per Diluted Share (EPS)
|
$
|
0.08
|
$
|
0.06
|
$
|
0.13
|
||||
Key
Non-GAAP Operating Results
|
Q3
08
|
Q2
08
|
Q3
07
|
|||||||
Non-GAAP
Operating Expense
|
$
|
48.5M
|
$
|
55.8M
|
$
|
44.9M
|
||||
Non-GAAP
Net Profit
|
$
|
7.4M
|
$
|
4.0M
|
$
|
9.5M
|
||||
Non-GAAP
Earnings Per Diluted Share (EPS)
|
$
|
0.11
|
$
|
0.06
|
$
|
0.13
|
Revenue
by Channel:
|
Q3
08
|
Q3
08/Q2 08
%
Change
|
Q3
08/Q3 07
%
Change
|
|||||||
U.S.
Orthodontists
|
$
|
22.3
|
(4.2
|
)%
|
(0.8
|
)%
|
||||
U.S.
GP Dentists
|
$
|
35.2
|
(3.9
|
)%
|
1.0
|
%
|
||||
International
|
$
|
15.1
|
(8.0
|
)%
|
31.1
|
%
|
||||
Training
and Other
|
$
|
2.6
|
(28.3
|
)%
|
(1.3
|
)%
|
||||
Total
Revenue
|
$
|
75.2
|
(5.9
|
)%
|
5.2
|
%
|
Average
Selling Price (ASP):
|
Q3
08
|
Q3
08/Q2 08
%
Change
|
Q3
08/Q3 07
%
Change
|
|||||||
Total
Worldwide Blended ASP
|
$
|
1,390
|
0.0
|
%
|
5.3
|
%
|
||||
Total
Worldwide ASP excluding Invisalign Express
|
$
|
1,500
|
0.0
|
%
|
4.9
|
%
|
||||
U.S.
Orthodontists Blended ASP
|
$
|
1,290
|
0.0
|
%
|
4.9
|
%
|
||||
U.S.
GP Dentists Blended ASP
|
$
|
1,360
|
1.5
|
%
|
3.8
|
%
|
||||
International
|
$
|
1,660
|
(2.4
|
)%
|
5.1
|
%
|
Number
of Cases Shipped:
|
Q3
08
|
Q3
08/Q2 08
%
Change
|
Q3
08/Q3 07
%
Change
|
|||||||
U.S.
Orthodontists – Full Invisalign
|
15,000
|
1.1
|
%
|
(1.1
|
)%
|
|||||
U.S.
Orthodontists – Invisalign Express
|
2,970
|
(8.6
|
)%
|
(5.1
|
)%
|
|||||
U.S.
GP Dentists – Full Invisalign
|
21,070
|
(4.8
|
)%
|
(3.7
|
)%
|
|||||
U.S.
GP Dentists – Invisalign Express
|
4,620
|
(7.0
|
)%
|
0.4
|
%
|
|||||
International–
Full Invisalign
|
8,950
|
(6.0
|
)%
|
25.0
|
%
|
|||||
International–
Invisalign Express
|
190
|
18.8
|
%
|
46.2
|
%
|
|||||
Total
Cases Shipped
|
52,800
|
(3.8
|
)%
|
1.4
|
%
|
Number
of Doctors Cases were Shipped to:
|
Q3
08
|
|||||||||
U.S.
Orthodontists
|
3,730
|
|||||||||
U.S.
GP Dentists
|
10,920
|
|||||||||
International
|
2,900
|
|||||||||
Total
Doctors Cases were Shipped to Worldwide
|
17,550
|
|||||||||
Number
of Doctors Trained Worldwide:
|
Q3
08
|
Cumulative
|
||||||||
U.S.
Orthodontists
|
90
|
8,600
|
||||||||
U.S.
GP Dentists
|
1,030
|
31,300
|
||||||||
International
|
330
|
13,670
|
||||||||
Total
Doctors Trained Worldwide
|
1,450
|
53,570
|
||||||||
Multiple
Case Doctors (Cumulative as of):
|
Q3
08
|
|||||||||
U.S.
Orthodontists
|
90.6
|
%
|
||||||||
U.S.
GP Dentists
|
86.4
|
%
|
||||||||
International
|
77.3
|
%
|
||||||||
Doctors
Starting Invisalign Treatment (Cumulative as of):
|
Q3
08
|
|||||||||
U.S.
Orthodontists
|
7,030
|
|||||||||
U.S.
GP Dentists
|
24,900
|
|||||||||
International
|
7,740
|
|||||||||
Total
Doctors Starting Invisalign Treatment
|
39,670
|
|||||||||
Doctor
Utilization Rates*:
|
Q3
08
|
Q2
08
|
Q3
07
|
|||||||
U.S.
Orthodontists
|
4.8
|
4.9
|
4.9
|
|||||||
U.S.
GP Dentists
|
2.4
|
2.5
|
2.6
|
|||||||
International
|
3.2
|
3.3
|
3.1
|
|||||||
Total
Utilization Rate
|
3.0
|
3.1
|
3.2
|
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||
|
September 30,
2008
|
September 30,
2007
|
September 30,
2008
|
September 30,
2007
|
|||||||||
Net
revenues
|
$
|
75,173
|
$
|
71,451
|
$
|
229,851
|
$
|
211,815
|
|||||
Cost
of revenues
|
18,766
|
18,132
|
58,617
|
55,908
|
|||||||||
Gross
profit
|
56,407
|
53,319
|
171,234
|
155,907
|
|||||||||
Operating
expenses:
|
|||||||||||||
Sales
and marketing
|
28,214
|
24,226
|
88,737
|
71,729
|
|||||||||
General
and administrative
|
14,395
|
13,949
|
45,905
|
38,014
|
|||||||||
Research
and development
|
5,918
|
6,749
|
20,214
|
19,117
|
|||||||||
Restructuring
|
2,189
|
-
|
2,189
|
-
|
|||||||||
Patients
First Program
|
-
|
-
|
-
|
(1,796
|
)
|
||||||||
|
|||||||||||||
Total
operating expenses
|
50,716
|
44,924
|
157,045
|
127,064
|
|||||||||
Profit
from operations
|
5,691
|
8,395
|
14,189
|
28,843
|
|||||||||
Interest
and other income, net
|
264
|
1,108
|
1,673
|
2,243
|
|||||||||
Profit
before income taxes
|
5,955
|
9,503
|
15,862
|
31,086
|
|||||||||
Provision
for income taxes
|
(798
|
)
|
(43
|
)
|
(1,371
|
)
|
(1,030
|
)
|
|||||
Net
profit
|
$
|
5,157
|
$
|
9,460
|
$
|
14,491
|
$
|
30,056
|
|||||
Net
profit per share
|
|||||||||||||
-
basic
|
$
|
0.08
|
$
|
0.14
|
$
|
0.21
|
$
|
0.45
|
|||||
-
diluted
|
$
|
0.08
|
$
|
0.13
|
$
|
0.21
|
$
|
0.42
|
|||||
Shares
used in computing net profit per share
|
|||||||||||||
-
basic
|
67,367
|
67,970
|
68,330
|
66,709
|
|||||||||
-
diluted
|
68,704
|
72,230
|
69,906
|
71,058
|
September 30,
2008
|
December 31,
2007
|
||||||
ASSETS
|
|||||||
Current
assets:
|
|||||||
Cash
and cash equivalents
|
$
|
79,756
|
$
|
89,140
|
|||
Marketable
securities, short-term
|
34,499
|
38,771
|
|||||
Accounts
receivable, net
|
48,872
|
44,850
|
|||||
Inventories,
net
|
3,015
|
2,910
|
|||||
Other
current assets
|
7,412
|
8,846
|
|||||
Total
current assets
|
173,554
|
184,517
|
|||||
Property
and equipment, net
|
29,568
|
25,320
|
|||||
Goodwill
and intangible assets, net
|
8,966
|
11,093
|
|||||
Other
long-term assets
|
4,432
|
1,831
|
|||||
Total
assets
|
$
|
216,520
|
$
|
222,761
|
|||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
|||||||
Current
liabilities:
|
|||||||
Accounts
payable
|
$
|
7,485
|
$
|
9,222
|
|||
Accrued
liabilities
|
33,877
|
39,875
|
|||||
Deferred
revenues
|
15,380
|
12,362
|
|||||
Total
current liabilities
|
56,742
|
61,459
|
|||||
Other
long term liabilities
|
124
|
148
|
|||||
Total
liabilities
|
56,866
|
61,607
|
|||||
Total
stockholders' equity
|
159,654
|
161,154
|
|||||
Total
liabilities and stockholders' equity
|
$
|
216,520
|
$
|
222,761
|
Three Months Ended
|
||||||||||
September 30,
2008
|
June 30,
2008
|
September 30,
2007
|
||||||||
GAAP
Operating expenses
|
$
|
50,716
|
$
|
55,787
|
$
|
44,924
|
||||
Restructuring
Cost
|
(2,189
|
)
|
-
|
-
|
||||||
Non-GAAP
Operating expenses
|
$
|
48,527
|
$
|
55,787
|
$
|
44,924
|
Three Months Ended
|
||||||||||
September 30,
2008
|
June 30,
2008
|
September 30,
2007
|
||||||||
GAAP
Net profit
|
$
|
5,157
|
$
|
4,030
|
$
|
9,460
|
||||
Restructuring
|
2,189
|
-
|
-
|
|||||||
Tax
effect on Restructuring
|
85
|
-
|
-
|
|||||||
Non-GAAP
Net profit
|
$
|
7,431
|
$
|
4,030
|
$
|
9,460
|
||||
Diluted
Net profit per share:
|
||||||||||
GAAP
|
$
|
0.08
|
$
|
0.06
|
$
|
0.13
|
||||
Non-GAAP
|
$
|
0.11
|
$
|
0.06
|
$
|
0.13
|
||||
Shares
used in computing diluted net profit per share
|
68,704
|
69,916
|
72,230
|
Q4
2008
|
FY
2008
|
||||||||||||||||||
GAAP
|
Adjustment
|
(a) |
Non-GAAP
|
FY
2008
|
Adjustment
|
(a) |
Non-GAAP
|
||||||||||||
Net
Revenue
|
$72.5
- $76.5
|
$72.5
- $76.5
|
$302.5
- $306.5
|
$302.5
- $306.5
|
|||||||||||||||
|
|||||||||||||||||||
Gross
Margin
|
72.5%
- 73.0%
|
|
72.5%
- 73.0%
|
|
74.0%
- 74.1%
|
|
74.0%
- 74.1%
|
|
|||||||||||
|
|||||||||||||||||||
Operating
Expenses
|
$52.1
- $53.6
|
$4.0
|
(a)
|
$48.1
- $49.6
|
$209.1
- $210.6
|
$6.2
|
(a)
|
$202.9
- $204.4
|
|||||||||||
|
|
||||||||||||||||||
Net
Profit %
|
1%
- 3%
|
|
5%
|
|
6%
- 8%
|
|
5%
- 6%
|
|
2%
|
|
7%
- 8%
|
|
|||||||
|
|
||||||||||||||||||
Net
Profit per Diluted Share
|
$0.01
- $0.03
|
$0.05
- $0.06
|
$0.06
- $0.09
|
$0.22
- $0.24
|
$0.09
|
$0.31
- $0.33
|
|||||||||||||
|
|
||||||||||||||||||
Stock
Based Compensation Expense:
|
|
||||||||||||||||||
Cost
of Revenues
|
$0.4
|
$0.4
|
$1.7
|
$1.7
|
|||||||||||||||
Operating
Expenses
|
$3.7
|
$3.7
|
$15.6
|
$15.6
|
|||||||||||||||
Total
Stock Based Compensation Expense
|
$4.1
|
$4.1
|
$17.3
|
$17.3
|
|||||||||||||||
Increase
in Deferred Revenue
|
$5.0
- $8.0
|
$5.0
- $8.0
|
|||||||||||||||||
Total Deferred Revenue Balance |
$17.0
- $20.0
|
$17.0
- $20.0
|
(a)
Restructuring charges
|
|||||||||||||||||||
Business
Metrics:
|
|||||||||||||||||||
|
Q4 2008
|
FY 2008
|
|||||||||||||||||
Case
Shipments
|
52.5K
- 55.0K
|
211.9K
- 214.4K
|
|||||||||||||||||
Cash
|
$115M
- $120M
|
$115M
- $120M
|
|
||||||||||||||||
DSO
|
~59
days
|
~59
days
|
|||||||||||||||||
Capex
|
$3.0M
- $5.0M
|
$15.0M
- $17.0M
|
|
||||||||||||||||
Depreciation
& Amortization
|
$2.0M
- $3.0M
|
$13.0M
- $14.0M
|
|||||||||||||||||
Diluted
Shares Outstanding
|
68.1
|
69.4
|